THE EFFICACY, SAFETY AND TOLERABILITY OF ANTIMICROBIAL DRUGS IN THERAPY FOR ASSOCIATED UROGENITAL INFECTIONS
- Autores: Rakhmatulina M.R.1
-
Afiliações:
- State Dermatovenereology Research Center, Russian Agency for Medical Technologies
- Edição: Nº 1 (2011)
- Páginas: 95-100
- Seção: Articles
- URL: https://journals.eco-vector.com/0300-9092/article/view/246543
- ID: 246543
Citar
Texto integral
Acesso aberto
Acesso está concedido
Acesso é pago ou somente para assinantes
Acesso está concedido
Acesso é pago ou somente para assinantes
Resumo
Objective. To study the efficacy of safocid in patients with sexually transmitted infections (urogenital trichomoniasis, chlamydial infection, Mycoplasma genitalium-associated urogenital diseases), nonspecific urogenital infectious diseases (bacterial vaginosis, urogenital candidiasis) and in their sexual partners. Subjects and methods. The study enrolled 50 patients (25 married couples) aged 18 to 45 years. All the patients received therapy with safocid given in a single oral dose of all 4 tablets contained in a blister pack. Results. The performed therapy could eradicate pathogenic and opportunistic agents in 98 and 96% of cases, respectively. Monitoring of vital functions revealed no clinically important abnormalities in any of the examinees. Conclusion. Safocid (a set of tablets) may be recommended for therapy of urogenital infectious diseases since it is a highly effective and easy-to-use drug showing a low frequency of side effects.
Texto integral
Sobre autores
M. Rakhmatulina
State Dermatovenereology Research Center, Russian Agency for Medical Technologies
Email: rahmatulina@cnikvi.ru
Bibliografia
- Антибактериальная терапия. Практическое руководство / Под. ред. Л.С. Страчунского, Ю.Б. Белоусова, С.Н. Козлова. — М., 2000.
- Воронова О.А., Герасимова Н.М., Вишневская И.Ф., Кобенко Э.Г. Клинико-эпидемиологические особенности хронического аэробного вагинита. Актуальные вопросы терапии инфекций, передаваемых половым путем, и дерматозов. — Екатеринбург, 2002. — С. 58—59.
- Кира Е.Ф. Бактериальный вагиноз. — СПб.: ООО «Нева-Люкс», 2001.
- Падейская Е.Н. Препараты группы 5-нитроимидазолов для лечения анаэробных и протозойных инфекций // Инфекции и антимикроб. тер. — 2000. — № 4. — С. 110—117.
- Kleimann D., Sarov I., Insler V. The effects of contraceptive hormones on the replication of Clamydia trachomatis in human endometrial cells // Contraception. — 1987. - Vol. 35, № 6. — Р. 533—542.
- Kohl K.S., Markowitz L.E., Koumans E.H. Developments in the screening for Chlamydia trachomatis: a review // Obstet. Gynecol. Clin. N. Am. — 2003. — Vol. 30, № 4. — Р 637—658.
- Moss T.R. Human genital infections with C. trachomatis. — 2001.
- Ripa K.T. Biological principles of the culture of Chlamydia trachomatis cells monolayers // Scand. J. Infect.Dis. — 1982. — Suppl. 32. — P. 25-29.
- Upcroft P., Upcroft J.A. Drug targets and mechanisms of resistance in the anaerobic protozoa // Clin. Microbiol. Rev. — 2001. — Vol. 14, № 1. — P. 150—164.
- World Health Organization (WHO). Global prevalence and incidence of selected curable sexually transmitted infections: overview and estimates. Geneva: WHO, 2001.